• Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium France
  • Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Germany
  • Study Comparing Gemcitabine and Mitomycin for Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden
  • Study of Cabozantinib in Adults with Advanced Low-Grade Neuroendocrine Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany
  • Study on the Safety and Effects of Tulisokibart for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Poland
  • Study on the Safety and Effectiveness of Fostemsavir for Patients with Multi-drug Resistant HIV-1 Who Have Had Extensive Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Romania
  • Study on the Long-Term Safety of Nintedanib for Children and Adolescents with Interstitial Lung Disease

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Greece Italy Norway +2
  • Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    2 1 1
    Belgium Denmark France Germany Italy The Netherlands +1
  • Study on the Effects of AZD4604 on Airway Inflammation in Adults with Asthma

    Not recruiting

    2 1
    Investigated diseases:
    Denmark Germany Spain
  • Study on Atropine Sulfate Eye Drops to Slow Down Myopia in European Children

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Germany

powered by